Bolt Biotherapeutics, Inc.
BOLT
$5.44
$0.29385.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.49% | -76.83% | -100.00% | -54.87% | -11.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.49% | -76.83% | -100.00% | -54.87% | -11.03% |
| Cost of Revenue | -51.42% | -40.87% | -28.18% | -7.80% | -1.35% |
| Gross Profit | 59.78% | 22.41% | 17.64% | -1.78% | 0.37% |
| SG&A Expenses | -27.86% | -34.47% | -28.66% | -34.05% | -13.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.76% | -40.37% | -28.30% | -15.10% | -4.51% |
| Operating Income | 51.61% | 29.12% | 20.73% | 9.57% | 4.03% |
| Income Before Tax | 59.61% | -2.12% | 10.99% | 6.65% | -17.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.61% | -2.12% | 10.99% | 6.65% | -17.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.61% | -2.12% | 10.99% | 6.65% | -17.38% |
| EBIT | 51.61% | 29.12% | 20.73% | 9.57% | 4.03% |
| EBITDA | 52.29% | 29.57% | 21.02% | 9.69% | 4.12% |
| EPS Basic | 59.84% | -1.39% | 11.79% | 7.58% | -16.21% |
| Normalized Basic EPS | 51.44% | 29.21% | 18.69% | 7.58% | 3.34% |
| EPS Diluted | 59.84% | -1.39% | 11.79% | 7.58% | -16.21% |
| Normalized Diluted EPS | 51.44% | 29.21% | 18.69% | 7.58% | 3.34% |
| Average Basic Shares Outstanding | 0.58% | 0.71% | 0.91% | 1.01% | 1.01% |
| Average Diluted Shares Outstanding | 0.58% | 0.71% | 0.91% | 1.01% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |